Special Issue

PARP Inhibitors in Cancer Therapy

Message from the Guest Editors

Over the past decade, poly(ADP-ribose) polymerases (PARPs) have emerged as a new target in cancer therapy. PARP inhibitors act through synthetic lethality with mutations in DNA repair genes and were approved for the treatment of BRCA-mutated ovarian and breast cancer. This Special Issue aims to provide a comprehensive overview of the evolving role of PARP inhibitors in oncology, from mechanistic insights and biomarkers of response to resistance mechanisms and novel therapeutic combinations. As we deepen our understanding of DNA repair pathways and tumor heterogeneity, the potential for PARP inhibitors continues to expand—offering new hope for precision oncology and personalized medicine. This Special Issue welcomes reviews, as well as original research articles.

Guest Editors

Dr. Jie Jiang

1. Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2. Department of Medicine, Harvard Medical School, Boston, MA 02215, USA

Dr. Fu Gui

Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

Deadline for manuscript submissions

30 June 2026

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/243240

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)